/AKYA

AKYA Stock - Akoya Biosciences, Inc.

Q: What is the analyst price target for AKYA?

Analyst price target information is not currently available for AKYA.

Q: What is AKYA's market cap?

Market capitalization information is not currently available for AKYA.

Healthcare|Medical - Instruments & Supplies|NASDAQ

$1.29-5.15%

$0.07 (-5.15%) • Jul 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+86.0%upside

Target: $2.40

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AKYA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.35

52W High$3.42

52W Low$0.93

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$81.67M	$96.63M	$74.86M	$54.92M	$42.44M
Gross Profit	$47.88M	$56.30M	$43.39M	$34.22M	$25.91M
Gross Margin	58.6%	58.3%	58.0%	62.3%	61.0%
Operating Income	$-46,730,000	$-57,668,000	$-66,208,000	$-37,225,000	$-11,492,000
Net Income	$-55,365,000	$-63,323,000	$-70,641,000	$-42,935,000	$-16,706,000
Net Margin	-67.8%	-65.5%	-94.4%	-78.2%	-39.4%
EPS	$-1.12	$-1.43	$-1.87	$-1.19	$-0.45

Company Overview

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

38%

Hold / Neutral

63%

Sell / Underperform

Analyst Consensus🔴 Bearish

3 Bullish5 Neutral/Bearish

Price Targets

$14

Average Target

↑ 957.6% Upside

Now

Low

$14

Average

$19

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 15th 2024	Craig Hallum	Downgrade	Hold	$5← $7
August 6th 2024	Morgan Stanley	Downgrade	Equal Weight	-
August 6th 2024	BTIG Research	Downgrade	Neutral	-
August 6th 2024	JP Morgan	Downgrade	Neutral	-
June 21st 2024	Craig Hallum	Initiation	Buy	$7.5
December 14th 2023	Guggenheim	Initiation	Neutral	-
July 5th 2023	JP Morgan	Resumed	Overweight	$18
February 2nd 2023	UBS	Initiation	Buy	$14
November 3rd 2022	CapitalOne	Initiation	Overweight	$19
October 6th 2022	Stephens	Initiation	Overweight	$16
June 22nd 2022	BTIG Research	Initiation	Buy	$16

Earnings History & Surprises

AKYA

Beat Rate

22%

Last 18 quarters

Avg Surprise

-109.9%

EPS vs Estimate

Beats / Misses

4/13

1 met exactly

Latest EPS

$-0.27

Q3 2025

EPS Surprise History

Q4 23

+29.7%

$-0.26vs$-0.37

Q1 24

+18.5%

$-0.22vs$-0.27

Q2 24

-16.7%

$-0.35vs$-0.30

Q3 24

0.0%

$-0.27vs$-0.27

Q4 24

+5.3%

$-0.18vs$-0.19

Q1 25

-13.3%

$-0.17vs$-0.15

Q2 25

-10.3%

$-0.32vs$-0.29

Q3 25

-22.7%

$-0.27vs$-0.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 4, 2025	$-0.22	$-0.27	-22.7%	✗ MISS
Q2 2025	May 12, 2025	$-0.29	$-0.32	-10.3%	✗ MISS
Q1 2025	Mar 17, 2025	$-0.15	$-0.17	-13.3%	✗ MISS
Q4 2024	Nov 14, 2024	$-0.19	$-0.18	+5.3%	✓ BEAT
Q3 2024	Aug 5, 2024	$-0.27	$-0.27	0.0%	= MET
Q2 2024	May 13, 2024	$-0.30	$-0.35	-16.7%	✗ MISS
Q1 2024	Mar 4, 2024	$-0.27	$-0.22	+18.5%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.37	$-0.26	+29.7%	✓ BEAT
Q3 2023	Aug 7, 2023	$-0.44	$-0.51	-15.9%	✗ MISS
Q2 2023	May 8, 2023	$-0.46	$-0.49	-6.5%	✗ MISS
Q1 2023	Mar 6, 2023	$-0.41	$-0.50	-22.0%	✗ MISS
Q4 2022	Nov 7, 2022	$-0.40	$-0.47	-17.5%	✗ MISS
Q3 2022	Aug 8, 2022	$-0.34	$-0.47	-38.2%	✗ MISS
Q2 2022	May 5, 2022	$-0.37	$-0.44	-18.9%	✗ MISS
Q1 2022	Mar 14, 2022	$-0.31	$-0.47	-51.6%	✗ MISS
Q4 2021	Nov 8, 2021	$-0.28	$-0.31	-10.7%	✗ MISS
Q3 2021	Aug 10, 2021	$-0.23	$-0.20	+13.0%	✓ BEAT
Q2 2021	May 18, 2021	$-0.15	$-2.85	-1800.0%	✗ MISS
Q2 2021	Apr 19, 2021	—	$-0.16	—	—
Q3 2020	Sep 30, 2020	—	$-0.15	—	—

Frequently Asked Questions about AKYA

What is AKYA's current stock price?

Akoya Biosciences, Inc. (AKYA) is currently trading at $1.29 per share. The stock has moved -5.15% today.

What is the analyst price target for AKYA?

The average analyst price target for AKYA is $2.40, based on 1 analyst.

What sector is Akoya Biosciences, Inc. in?

Akoya Biosciences, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.

What is AKYA's market cap?

Akoya Biosciences, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.

Does AKYA pay dividends?

No, Akoya Biosciences, Inc. does not currently pay a dividend to shareholders.